Assessment of the patient with benign prostatic hyperplasia
Carlin, B.I.; Resnick, M.L.
Comprehensive Therapy 22(9): 586-591
1996
ISSN/ISBN: 0098-8243 PMID: 8902350 Document Number: 460634
Document emailed within 1 workday
Related Documents
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Hartung, R. 1997: Updated patient information for treatment of benign prostatic hyperplasia: a permanent challenge European Urology 32(Suppl): 42-44
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Blanc, M.; Sacrini, A.; Avogadro, A.; Gattamorta, M.; Lazzerini, F.; Gattoni, F.; Cretti, F. 1998: Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia La Radiologia Medica 95(3): 182-187
Abdul-Muhsin, H.M.; Jakob, N.J.; McLemore, R.M.; McAdams, S.B.; Humphreys, M.R. 2016: Infectious complications associated with the use of temporary prostatic urethral stents in patients with benign prostatic hyperplasia Canadian Journal of Urology 23(5): 8465-8470
Pretlow, T.G.; Whitehurst, G.B.; Pretlow, T.P.; Hunt, R.S.; Jacobs, J.M.; McKenzie, D.R.; McDaniel, H.G.; Hall, L.M.; Bradley, E.L. 1982: Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia Cancer Research 42(11): 4842-4848
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Yu, X.-x.; Zhang, R.-m.; Zhou, D.-q.; Mo, Z.-n.; Li, W.-g.; Wang, Q.; Wang, J.; Jiang, B.; Deng, C.-h.; Pang, X. 2013: Transurethral plasmakinetic enucleation of prostate and suprapubic small cut in the treatment of high risk and senior patient with benign prostatic hyperplasia and bladder stones Zhonghua Yi Xue Za Zhi 93(8): 597-599
Maygarden, S.J.; Strom, S.; Ware, J.L. 1992: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia Archives of Pathology and Laboratory Medicine 116(3): 269-273
Schönberger, B. 1986: Benign prostatic hyperplasia Zentralblatt für Chirurgie 111(10): 569-588
Hiraoka, Y.; Sa, I. 2002: Biochemical diagnosis of benign prostatic hyperplasia (including differential diagnosis with prostatic carcinoma) Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 11): 342-345
Rodríguez, J.V. 2001: Prostatotomy in benign prostatic hyperplasia. Why? Archivos Espanoles de Urologia 54(7): 667-673
Neal, D.E.; Hegarty, P. 2003: Key questions in benign prostatic hyperplasia Practitioner 247(1652): 886-889
Tan, E.C. 1995: Pharmacotherapy in benign prostatic hyperplasia Annals of the Academy of Medicine Singapore 24(4): 615-618
Thomas, D. 1997: When to investigate benign prostatic hyperplasia Practitioner 241(1576): 408-413
Concato, J.; Horwitz, R.I.; Feinstein, A.R.; Elmore, J.G.; Schiff, S.F. 1993: Therapies for benign prostatic hyperplasia JAMA 269(7): 867
Garnett, S.; Abrams, P. 2001: Managing benign prostatic hyperplasia Practitioner 245(1627): 830